Remepy, a company developing a novel class of hybrid drugs, has successfully closed a $36 million Series A financing round. The investment was co-led by O.G. Venture Partners and M Ventures, the strategic venture arm of Merck KGaA, Darmstadt, Germany. This new capital injection brings the company's total funding to $62 million, fueling its mission to integrate prescription medicines with AI-driven therapeutic applications.
Pioneering a New Class of Medicine
Remepy is pioneering what it terms "Hybrid Drugs," which combine traditional pharmaceuticals with personalized, AI-powered therapeutic software. This innovative approach integrates pharmacological treatments with adaptive physical, cognitive, and behavioral interventions into a single, cohesive therapy. The goal is to deliver scalable, multidisciplinary care to a broader patient population through the standard prescription model.
The platform offers significant strategic value for pharmaceutical companies by creating new intellectual property and enabling effective lifecycle management for existing drugs. It also serves to differentiate both current and future medications in a competitive market. Furthermore, the personalized nature of the treatment aims to increase the success rates of clinical trials.
Strategic Allocation of New Capital
The proceeds from the Series A round are earmarked for several key growth areas within the company. Remepy will accelerate its pharmaceutical co-development partnerships and expand its proprietary Hybrid Drug pipeline and platform. A substantial portion of the funds will also support the global Phase III clinical development of its lead program.
This lead program, named Hybridopa, is a treatment developed for Parkinson's disease that has already shown promising results. Phase IIa clinical trials demonstrated notable improvements in both motor and non-motor symptoms, supported by peer-reviewed scientific publications. The company is now preparing for a global Phase III trial, which is scheduled to commence in the fourth quarter of 2026.
Growing Industry and Investor Confidence
The Hybrid Drug model is gaining considerable momentum, bolstered by emerging regulatory frameworks from bodies like the FDA for drug-software combination products. This growing alignment within the regulatory landscape is paving the way for broader industry acceptance and adoption. It signals a significant shift toward integrating digital health solutions with traditional pharmaceutical development.
Investor confidence in Remepy's vision is strong, with partners highlighting the company's unique position at the intersection of biotechnology, AI, and digital health. Ziv Kop of O.G. Venture Partners noted that Remepy is redefining how medicines are developed and delivered. This sentiment is echoed by other investors who see immense potential in transforming patient care through this integrated approach.
Founded in 2022 by a team of experienced entrepreneurs, Remepy has quickly established important industry ties. The company recently announced a strategic collaboration with Merck KGaA, Darmstadt, Germany, to co-develop Hybrid Drugs across multiple indications. This partnership will initially focus on creating new treatments for rare tumors, showcasing the platform's versatility.
This $36 million financing marks a pivotal moment for Remepy, providing the necessary resources to advance its clinical trials and expand its partnerships. The company is well-positioned to lead a new era in medicine where every drug is enhanced with personalized intelligence. Ultimately, this approach aims to maximize therapeutic impact and redefine the standards of patient care globally.